Researchers at the University of California, Davis have discovered small molecules to potentially treat malaria and Chagas disease as well as prevent transmission of these diseases.
Standard treatment for malaria, Chagas disease and other infectious diseases is the prophylactic use of antibiotics that target the arthropod-borne parasite. Although effective in treating the infected host, it does not prevent the transmission of the parasites and the wide spread use of prophylactics has led to an increase in drug resistant infective parasites. This, in turn, has limited the effectiveness of currently available prophylactics and lead to an increase in risk for transmission of the disease.
Researchers at the University of California, Davis have discovered small molecule inhibitors to potentially treat and prevent transmission of malaria and Chagas disease. This method has been successfully tested in mammalian cells at risk of exposure to an arthropod-borne parasite and parasitic blood meals to show efficacy against parasite infection and inhibiting disease transmission. Additionally, since the inhibitors target highly conserved regions found in mammals and arthropod hosts, drug resistance risk of the parasite for malaria and Chagas disease is significantly reduced.
|United States Of America||Issued Patent||9,918,989||03/20/2018||2013-939|
|United States Of America||Published Application||20160151380||06/02/2016||2013-939|
malaria, mosquito, anti-malarial, parasite, small molecule inhibitor, Chagas disease, arthropod, infectious disease, drug resistance, mosquito bite, parasitic protozoan, American trypanosomiasis, trypanosoma cruzi, T. cruzi, kissing bugs, blood, endemic area, vector borne transmission, host transmission, treatment